Drugs / [18F]MC225
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05853471 Comparator | Feb 2022 → Jan 2024 | Alzheimer disease, Parkinson disease, cognitive impairment with or without cerebellar ataxia | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MC225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05853471 ↗ |
| Modality | Diagnostic / imaging agent | “A novel PET tracer (\[18F\]MC225) was developed to measure the function of P-glycoprotein” NCT05853471 ↗ |